HOME >> BIOLOGY >> NEWS
First drug developed for widespread use against botulism

An eight-year research effort by university and military scientists in the U.S. has produced the first drug that can be mass-produced to prevent or treat botulism, the paralyzing disease caused by a nerve toxin that is considered one of the greatest bioterrorism threats.

The UCSF-led research is being published on line the week of August 5 by The Proceedings of the National Academy of Sciences.

Botulinum toxin, naturally produced by a soil bacterium, is the most poisonous substance known. A gram of the toxin, if evenly dispersed and inhaled, could kill a million people, according to a recent study. Yet no anti-botulism drugs are available which could be produced in the quantities needed for treatment or prevention if the toxin were used for bioterror, the new study points out. The new drug potently neutralizes botulinum toxin and can be readily mass-produced, the researchers report.

The drug was developed by expanding the technique now used to produce monoclonal antibodies against pathogens or other molecular targets. Scientists isolated and identified three antibodies against botulinum toxin and combined them. Each antibody is capable of binding to a different part of the toxin molecule. When administered together, they bind the toxin much more tightly and block far more of the toxin surface than a single antibody could, the scientists report. As a result, in animal studies, the antibody "cocktail" neutralizes much more of the toxin than observed for single antibodies.

Treatment for botulinum poisoning usually requires many weeks of intensive-care hospitalization, and exposure of even a small number of people would seriously disrupt health care delivery in any major city, according to a recent assessment. A vaccine has been developed, but widespread use is not currently being considered, the researchers say, since the likelihood of exposure is uncertain. Also, vaccination would block accepted treatments for a number of overactive mu
'"/>

Contact: Wallace Ravven
wravven@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
5-Aug-2002


Page: 1 2 3

Related biology news :

1. First glimpse of DNA binding to viral enzyme
2. First clinical study of new pediatric croup vaccine shows safety, tolerability in adults
3. 2nd media alert First Scientific Conference on Childhood Leukaemia
4. First International Scientific Conference on Childhood Leukaemia
5. First ever standards linking climate change, biodiversity and poverty seek global peer review
6. First genetic comparison of purebred domestic dogs produces surprises
7. First time in the U.S.: Saint Louis University tests third-generation vaccine against smallpox
8. First target for childhood malaria vaccine
9. First study of resveratrol dietary supplement finds effect on breast and prostate cancers unlikely
10. First flavors form a lasting impression
11. STN International launches Derwent World Patents Index First View

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/4/2019)... ... ... Harper was three years old when her owners took her to the veterinarian ... in the joints. She was referred to a veterinary specialist to perform “salvage ... Christopher Eich of Southern California Veterinary Specialty Hospital , examined Harper and recommended ...
(Date:5/31/2019)... ... May 29, 2019 , ... ... Windows and mobile, announces the launch of version 13.1. The new version extends ... Management API, and supports Apple’s spring release functionality. Version 13.1 builds on FileWave’s ...
(Date:5/26/2019)... (PRWEB) , ... May 24, 2019 , ... Zolgensma (Novartis, ... as AVXS-101, was approved for clinical use in the United States by the Food ... virally-delivered gene therapy approved to treat inherited genetic disorders in the United States and ...
Breaking Biology News(10 mins):
(Date:6/11/2019)... , ... June 11, 2019 , ... ... Personalized Stem Cells Inc. (PSC) , has announced that their GMP facility ... Food and Drug Branch for manufacturing. This is an important milestone for ...
(Date:6/6/2019)... ... 05, 2019 , ... WCCT Global, Inc ., a full-service early phase ... they will be receiving 3 awards at the 2019 CRO Leadership Awards, to be ... the categories of overall Quality and Compatibility (Access to desired markets, cultural fit, timely ...
(Date:5/31/2019)... Redwood City, California (PRWEB) , ... ... ... received allowance of our patent applications from the USPTO providing proprietary interest ... SYSTEM AND METHOD FOR SLEEP DISORDER DIAGNOSIS AND TREATMENT… extends Somnology’s IP ...
(Date:5/31/2019)... ... May 30, 2019 , ... Object ... announce the strategic acquisition of Metabiologics, Inc., a globally recognized leader in the ... ownership and commercialization rights to a full spectrum of botulinum neurotoxins, as well ...
Breaking Biology Technology:
Cached News: